FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Seven Drugmakers Face Senate Grilling on Pricing

March 5, 2019

The Senate Finance Committee quizzed senior executives from seven leading drugmakers last week, calling on them to justify the sky-high prices of their prescription drugs.

The witnesses from AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi did their best to deflect some of the blame to health insurance companies, pharmacy benefit managers and rebates.

But the committee’s chairman, Sen. Chuck Grassley (R-Iowa), had other ideas. “We cannot allow anyone to hide behind the current complexities that shield the true cost of drugs, and we shouldn’t turn a blind eye to industry’s practices that thwart laws and regulations designed to promote competition and generic drug entries into the marketplace,” he said.

View today's stories